A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerPanagiotis A. Konstantinopoulos, Ronnie Shapira‐Frommer, Ignace Vergote et al.|Gynecologic Oncology|2022Cited by 66
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung CancerLauren A. Byers, Martin Förster, Alejandro Navarro et al.|Clinical Lung Cancer|2021Cited by 39
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G. Wierda, Paolo Ghia, Nirav N. Shah et al.|The Lancet Haematology|2024Cited by 37